Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993392 · ClinicalTrials.gov registry record · Phase 4
SUBLOCADE Rapid Initiation Study
A Phase 4 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT03993392 is a Phase 4 study that has completed, run by Indivior. The registered enrollment target is 26 participants.
The verdict
NCT03993392, a Phase 4 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.
Interventions
- DRUG TM buprenorphine
- DRUG SUBLOCADE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2019-12-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993392
The ClinicalTrials.gov registry entry for NCT03993392 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TM buprenorphine is the first listed.
NCT03993392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03993392 about?
NCT03993392 is a clinical study titled "SUBLOCADE Rapid Initiation Study". This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.
What is the current status of trial NCT03993392?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2019-08-29. Estimated completion is 2019-12-26.
What interventions are being tested in trial NCT03993392?
The interventions under investigation include: TM buprenorphine (DRUG), SUBLOCADE (DRUG).
Who is sponsoring clinical trial NCT03993392?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.